---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-089563"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T17:14:41.362123+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Carisma Q2 net loss $19.9M, cash $117.1M; dosed first patient in CT-0508+KEYTRUDA combo trial

## Summary
- Dosed first patient in Phase 1 trial of CT-0508 in combination with KEYTRUDA for HER2-overexpressing solid tumors.
- Nominated additional oncology target under Moderna collaboration; total of five nominated targets.
- Cash, cash equivalents and marketable securities $117.1M as of June 30, 2023 (down from $139.0M Q1 2023); expected to fund through end of 2024.
- Net loss $19.9M for Q2 2023 vs $14.8M for Q2 2022; R&D expenses increased to $18.5M from $14.2M.
- Appointed Eric Siegel as General Counsel and Terry Shields as SVP of Human Resources.

## SEC filing metadata
- accession: 0001104659-23-089563
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000110465923089563/0001104659-23-089563-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000110465923089563/tm2322975d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-089563
- JSON: https://secwatch.observer/filing/0001104659-23-089563.json
- Plain text: https://secwatch.observer/filing/0001104659-23-089563.txt

## Key facts
- Earnings Releases
  Carisma Therapeutics Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $19.9 million for the second quarter of 2023.
  - Period: the quarter ended June 30, 2023
  - Net income: Net loss was $19.9 million for the second quarter of 2023
  - Result: reported results
  source text: Carisma Therapeutics Inc. (the “Company”) announced its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1485003/000110465923089563/0001104659-23-089563-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.